Thread by @parthaskar

GLP1-RA trials #T2Diabetes showing attenuation of nephropathy:
(Nb: Dulaglutude reports tomorrow)
Points of note?
1. In “good” renal function
2. As secondary outcome
3. Overarching outcome driven by reduction of persistent macroalbuminiuria

#ADA2019

Summary of action and possible mechanism of GLP-1RA on kidneys #ADA2019

A one slide overview of all GLP-1RA results in the cardiovascular space ...so far
#ADA2019

A wonderful summary of GLP-1RA and potential mechanisms in the CV space
#ADA2019

Next up: Potential mechanisms of renoprotection with SGLT2-I class of drugs

A very relevant slide to show additive effect of SGLT2-I on renal perfusion - along with RAAS blockade
#ADA2019

Very relevant point made about low risk patients in previous trials looking at Renal outcomes - and how CREDENCE was different in patient characteristic
#ADA2019

And why do nephrologists like CREDENCE?
It’s the type of patients and at what stage they are - regards kidney disease
Very beautifully explained!!
#ADA2019

A brilliant summary from a nephrology colleague and overview of SGLT2-I and it’s effect on Renal outcomes
#ADA2019